61-year-old man with left calf swelling on hospital day 6
A 61-year-old municipal water plant operator is admitted for acute gallstone pancreatitis. He receives intravenous fluid resuscitation, analgesia, and subcutaneous unfractionated heparin every 8 hours for venous thromboembolism prophylaxis. By hospital day 6, his abdominal pain has resolved and he has resumed a regular diet. However, he reports new aching and swelling in his left calf that began overnight. Temperature is 36.8 C (98.2 F), blood pressure is 134/82 mm Hg, pulse is 76/min, and respirations are 14/min. Physical examination reveals left calf fullness with mild pitting edema and tenderness to gentle compression. Laboratory studies show a platelet count of 94,000/mm3 (admission baseline: 278,000/mm3), hemoglobin of 13.8 g/dL, leukocyte count of 7,400/mm3, and serum creatinine of 2.4 mg/dL (admission baseline: 1.1 mg/dL). Compression ultrasonography confirms a non-compressible left popliteal vein. Which of the following is the most appropriate next step in management?
See the answer and explanation below:
Post-Call Recovery Reads
Finished your notes? Time to swap the pager for a crown. Kingdoms of Silent Sorrows is the ultimate 'brain-break', a high-stakes fantasy featuring a Fae princess, a Vampire king, and an enemies-to-lovers arc that will actually make you forget about your rounding list. No p-values, just fated mates and forbidden magic.
View on AmazonThe Correct Answer
C
Explanation
Clinical Pearl:
When heparin-induced thrombocytopenia is suspected, all heparin products must be discontinued immediately and therapeutic anticoagulation with a non-heparin agent initiated. In patients with concurrent renal insufficiency, argatroban is the direct thrombin inhibitor of choice due to its hepatic clearance.
Explanation:
This patient has heparin-induced thrombocytopenia with thrombosis, evidenced by a greater than 50% decrease in platelet count occurring on day 6 of heparin exposure and a newly confirmed deep vein thrombosis, yielding a high-probability 4Ts score of 8. According to current hematology society guidelines, patients with a high clinical pretest probability of heparin-induced thrombocytopenia require immediate cessation of all heparin products and initiation of therapeutic non-heparin anticoagulation, with intravenous argatroban being the preferred agent in the setting of renal insufficiency because of its biliary elimination. Discontinuing heparin alone while merely monitoring serial platelet counts is inadequate, as the cumulative risk of new or progressive thrombosis approaches 50% over the subsequent 30 days without active non-heparin anticoagulation. Initiating oral warfarin monotherapy in acute heparin-induced thrombocytopenia is contraindicated because it rapidly depletes protein C before reducing prothrombin levels, creating a transient prothrombotic state that can precipitate venous limb gangrene and skin necrosis. Switching to subcutaneous enoxaparin is strictly contraindicated because low-molecular-weight heparins exhibit greater than 90% in vitro cross-reactivity with circulating antibodies directed against the platelet factor 4-heparin complex. Transfusing pooled platelets is contraindicated in the absence of active life-threatening hemorrhage, as administering exogenous platelets fuels antibody-mediated platelet activation and increases the risk of catastrophic arterial and venous thrombosis.
See you tomorrow morning!